Clinical Experience with Recombinant Human Thyrotrophin (rhTSH) in the Management of Patients with Differentiated Thyroid Cancer
- 1 April 2000
- journal article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 15 (2) , 211-217
- https://doi.org/10.1089/cbr.2000.15.211
Abstract
The purpose of this work was to gain clinical experience with and to identify the optimal conditions for the use of recombinant human TSH (rhTSH, commercially available as Thyrogen) in the management of patients with differentiated thyroid cancer (DTC). The study involved 22 patients for a total of 27 administration cycles of rhTSH, for either diagnostic (in 19 instances) and/or therapeutic purposes (in 8 instances). There were 19 patients with papillary cancer (follicular variant in 4, columnar variant in 1) and 3 patients with follicular cancer (1 Hurtle cell variant). All patients had previously undergone total thyroidectomy and 1-5 cycles of 131I-therapy. Thyrogen was administered i.m. according to the suggested protocol: 0.9 mg i.m. on days 1 and 2, radioiodine on day 3. Peak serum TSH levels between 68-237 microIU/mL were observed after rhTSH administration; these were on average 65% higher, on a patient-by-patient basis, than peak serum TSH observed after conventional withdrawal of thyroxine treatment in 19 patients, while in 3 patients they were 28% lower, but still in the potent stimulation range (86-94 microIU/mL). There was general agreement between imaging results obtained under rhTSH stimulation and those obtained on prior occasions during thyroxine withdrawal, although radioiodine uptake was interpreted as less intense following Thyrogen administration. Of 18 patients undergoing rhTSH administration for diagnostic purposes, 11 patients had a negative radioiodine whole-body scan (WBS) and 7 had a positive WBS. Three of the WBS-negative patients were shown to be actually affected by tumor recurrence, respectively by PET with [18F]FDG (in 2 cases) and by post-131I therapy scan. Serum thyroglobulin (hTg) increased to abnormal levels following rhTSH stimulation in 3/7 of the WBS-positive patients as well as in 1/11 WBS-negative patients. In 3/7 WBS-positive as well as in 3/11 WBS-negative patients, serum hTg progressively rose under rhTSH stimulation, yet still remaining below 3 ng/mL. Post-131I therapy scans following Thyrogen administration showed good radioiodine uptake in 7/8 patients, the single unsuccessful case being most likely due to expansion of the iodine pool because of recent use of an iodinated contrast medium. The overall results show the feasibility and practical advantages of employing rhTSH stimulation in the general clinical setting rather than thyroxine withdrawal in the management of DTC patients. Caution should be raised on the interpretation of the serum hTg response to such potent but short-lived TSH stimulation.Keywords
This publication has 10 references indexed in Scilit:
- Detection of Residual and Recurrent Differentiated Thyroid Carcinoma by Serum Thyroglobulin MeasurementThyroid®, 1999
- Cancer incidence and mortality, 1973-1995Cancer, 1998
- Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone TherapyThyroid®, 1997
- Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990European Journal Of Cancer, 1997
- Thyroid Remnant 131I Ablation for Papillary and Follicular Thyroid CarcinomaThyroid®, 1997
- Prognostic factors for thyroid carcinomaCancer, 1997
- Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessmentAnnals of Oncology, 1995
- Recombinant Human Thyroid-Stimulating Hormone: Initial Bioactivity Assessment using Human Fetal Thyroid Cells*Journal of Clinical Endocrinology & Metabolism, 1991
- Biological Activity and Metabolic Clearance of a Recombinant Human Thyrotropin Produced in Chinese Hamster Ovary CellsEndocrinology, 1991
- SERUM THYROGLOBULIN CONCENTRATIONS AND 131I WHOLE BODY SCANS IN THE DIAGNOSIS OF METASTASES FROM DIFFERENTIATED THYROID CARCINOMA (AFTER THYROIDECTOMY)Clinical Endocrinology, 1980